That SHP2 pY62 is highly prevalent in solid tumors, despite the rarity of PTPN11 mutations, indicate that SHP2 activation in solid tumors occurs predominantly by post-translational modification or through phosphopeptide binding rather than genomic alterations, which are more commonly seen in hematologic malignancies. This evidence concerns the gene PTPN11 and hematologic disorder.